๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (A new derivative of camptothecin)

โœ Scribed by Satoshi Nagai; Masaji Yamauchi; Toshiwo Andoh; Miwako Nishizawa; Tetsuya Satta; Yasuhiro Kodera; Ken Kondou; Seiji Akiyama; Katsuki Ito; Hiroshi Takagi


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
813 KB
Volume
59
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis


CPT-1 1 -resistant human gastric and colonic xenograft lines were established by direct intratumoral injection of CPT-11 into subcutaneous SC-1-NU and CC-2-NU tumors in nude mice once a week for 10 months. The resistance of these xenograft lines to CPT-11 was confirmed by growth inhibition rate, to be 36.3% and 45.4%, respectively, compared to each parent cell line. DNA topoisomerase I activity of the nuclear extracts of SC-1 -NU/CPT-1 1 and CC-2-NUKFT-1 1, as assayed by relaxation of supercoiled DNA Col-El, was significantly less than those of the parent lines. The cellular levels of topoisomerase I in those resistant lines measured by Western blot analysis were 0.57-and 0.79-fold lower than those of the parental lines, respectively. However, the activity of DNA topoisomerase I1 of those resistant cell lines assayed by decatenation of kinetoplast DNA was higher than that of the parental lines and the cellular levels of topoisomerase I1 in the resistant lines measured by Western blot analysis were 10.8-and 8. l-fold higher than those of the parent lines. Intracellular accumulation of CPT-11 in CPT-1 l-resistant tumors was not changed as compared to that of the parental lines, but hydrolysis of CPT-11 to more active SN-38 was reduced in the resistant tumors.


๐Ÿ“œ SIMILAR VOLUMES


CPT-11 in human colon-cancer cell lines
โœ Willy J.M. Jansen; Bas Zwart; Saskia T.M. Hulscher; Giuseppe Giaccone; Herbert M ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 104 KB ๐Ÿ‘ 2 views

CPT-11, a new semisynthetic derivative of camptothecin, is active in a number of tumor types in the clinic, including colon cancer. CPT-11 is a drug that is converted into the active metabolite SN-38 by a carboxylesterase. Experiments were performed to obtain more insight in the cellular characteris